RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 1999; 82(05): 1516-1521
DOI: 10.1055/s-0037-1614864
DOI: 10.1055/s-0037-1614864
Rapid Communications
The Effects of Angiotensin Metabolites on the Regulation of Coagulation and Fibrinolysis in Cultured Rat Aortic Endothelial Cells
Weitere Informationen
Publikationsverlauf
Received
05. April 1999
Accepted after revision
07. Juli 1999
Publikationsdatum:
09. Dezember 2017 (online)
Summary
Not only angiotensin II (Ang II) but also other angiotensin metabolites such as angiotensin I (Ang I), angiotensin III (Ang III), angiotensin IV, or angiotensin 1-7 have recently been reported to have various activities. Few data, however, are available on the regulation of thrombus formation. In this study, we investigated the effects of angiotensin metabolites on the mRNA expression of tissue factor (TF), tissue factor pathway inhibitor (TFPI), plasminogen activator inhibitor-1 (PAI-1), and tissue type plasminogen activator (TPA) in cultured rat aortic endothelial cells. None of the used angiotensin metabolites altered TFPI or TPA mRNA expression levels. Ang I, Ang II, and Ang III made TF and PAI-1 mRNA inductions which were inhibited by an selective antagonist of angiotensin II type 1 receptors. These metabolites made TF predominant to TFPI or PAI-1 to TPA, and could render endothelial cells thrombogenic.
-
References
- 1 Johnston CI. Biochemistry and pharmacology of renin-angiotensin system. Drugs 1990; 39 (Suppl. 01) 21-31.
- 2 Peach MJ, Dostal DE. The angiotensin II receptor and the actions of angiotensin II. J Card Pharmacol 1990; 16: 525-30.
- 3 Gavras H, Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens 1991; 9: 385-92.
- 4 Garg R, Yusuf S. for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patient with heart failure. J Am Med Assoc 1995; 273: 1450-6.
- 5 Dzau VJ, Gibbons GH, Morishita R, Pratt RE. New perspectives in hypertension research. Potentials of vascular biology. Hypertension 1994; 6: 1132-40.
- 6 Welches WR, Santos RAS, Chappell MC, Brosnihan KB, Greene LJ, Ferrario CM. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. Hypertension 1991; 9: 631-8.
- 7 Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A, Tallant EA. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension 1991; 18 (suppl III) III-126-33.
- 8 Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 1992; 19 (suppl II) II-56-61.
- 9 Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993; 52: 1461-80.
- 10 Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 1997; 11 (05) 355-64.
- 11 Vaghy PL, Russell JS, Lantry LE, Stephens RE, Ward PE. Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocyte and fibroblast. Peptides 1995; 16 (08) 1367-73.
- 12 Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens Suppl 1994; 12 (04) S3-S10.
- 13 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
- 14 William FN. Tissue factor pathway inhibitor. Semir Thromb Hemost 1994; 20: 101-8.
- 15 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
- 16 Hajjar KA, Hamel NM, Harpel PC, Nachman RL. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-9.
- 17 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in transgenic mice for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-6.
- 18 Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diatheses due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1745-52.
- 19 Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, Kasahara T, Sugano T, Yoshizumi M, Sawada S, Nakagawa M. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1185-95.
- 20 McGuire PG, Orkin RW. Methods in laboratory investigation. Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab Invest 1987; 57: 94-105.
- 21 Aoyagi T, Tobe H, Kojima F, Hamada M, Takeuchi T, Umezawa H. Amastatin, an inhibitor of aminopeptidase A, produced by actinomycetes. J Antibiot (Tokyo) 1978; 31 (06) 636-8.
- 22 Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319: 80-6.
- 23 Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84-95.
- 24 Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with ejections. Lancet 1992; 340: 1173-8.
- 25 Campbell DJ, Kladis A. Valentijn Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995; 26: 233-40.
- 26 Yang HYT, Erds EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II, angiotensin I converting enzyme). J Pharmacol Exp Ther 1971; 117: 291-300.
- 27 Cheng DY, DeWitt BJ, McMahon TJ, Kadowitz PJ. Comparison of pressor responses to angiotensin I, II, and III in pulmonary vascular bed of cats. Am J Physiol 1994; 266 (06) (Suppl. 02) H2247-55.
- 28 Garrison EA, Santiago JA, Osei SY, Kadowitz PJ. Analysis of responses to angiotensin peptides in the hindquarters vascular bed of the cat. Am J Physiol 1995; 268 (06) (Suppl. 02) H2418-25.
- 29 Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265 (36) 22348-57.
- 30 Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmaco 1993; 62 (02) 207-10.
- 31 Catalioto R, Renzetti A, Criscuoli M, Mizrahi J, Subissi A. Angiotensins induce the release of prostacyclin from rabbit vas deferens: evidence for receptor heterogeneity. Eur J Pharmacol 1994; 256 (01) 93-7.
- 32 Tseng CJ, Chou LL, Ger LP, Tung CS. Cardiovascular effects of angiotensin III in brain stem nuclei of normotensive and hypertensive rats. J Pharmacol Exp Ther 1994; 268 (02) 558-64.
- 33 Radhakrishnan R, Sim MK. Enhanced pressor response to angiotensin III in spontaneously hypertensive rats: effects of losartan. Eur J Pharmacol 1994; 259: 87-90.
- 34 Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-20.
- 35 Campbell DJ, Kladis A, Duncan AM. Effects of converting inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-49.
- 36 Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides 1993; 14: 883-91.
- 37 Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 1: 104-8.
- 38 Drake TA, Morrissey JH, Edington TS. Selective cellular expression of tissue factor in human tissues. Implication for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
- 39 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
- 40 Hamsten A, Wiman B, de Faire U, Blombck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
- 41 Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997; 79 (5A) 12-6.
- 42 Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-20.
- 43 Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77 (03) 522-5.
- 44 Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patient with acute myocardial infarction. N Engl J Med 1992; 327: 678-84.